NBD-14270 - ≥99% , CAS No.2411819-82-2

CAS: 2411819-82-2 Cat. No.: N1422238 Formula: C₁₈H₁₈F₃N₅O₂S Peso molecolare: 425.43

GRADE & PURITY ≥99%

Storage

Store at 2-8°C,Protected from light,Desiccated

Shipped In

Wet ice

Panoramica

NBD-14270, a pyridine analogue, is a potent HIV-1 entry antagonist with an IC 50 of 180 nM against 50 HIV-1 Env-pseudotyped viruses. NBD-14270 binds to HIV-1 gp120 and shows potent antiviral activity. NBD-14270 shows low cytotoxicity (CC 50 >100 μM).

Specifications

Specifiche e purezza

≥99%

Condizioni di conservazione di stoccaggio

Store at 2-8°C,Protected from light,Desiccated

Spedito in

Wet ice

Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.

Tipo di azione

ANTAGONIST

Purezza

≥99%

Nomi e identificatori

Peso molecolare

425.43

Application Protocols

No tested application protocols (e.g., WB, IHC, IF, FC) or specific assay procedures are provided for this library compound.

General protocol template for small-molecule screening (research use only):

• Stock preparation: Dissolve compound in anhydrous DMSO to 10–50 mM. Vortex and, if necessary, gently warm (≤40 °C). Filter through 0.2 μm PTFE if particulates persist.
• Aliquoting: Dispense single-use aliquots (10–100 μL) into amber vials/plates to avoid repeated freeze–thaw.
• Working solutions: Dilute into assay buffer to desired concentrations, keeping final DMSO content within assay tolerance (typically 0.1–1% v/v). Include vehicle controls.
• Dose–response: Prepare serial dilutions (e.g., 1:3 or 1:2) across ≥8 points. Record exact concentrations and plate map.
• Data integrity: Confirm identity and purity by LC-MS before and after campaigns, and re-quantify stock concentrations by UV or qNMR if potency metrics are critical.

For any specialized application (photophysics, electrochemistry, covalent labeling), request the structure and CoA to ensure appropriate conditions and safety measures.

Biological Roles

Item-specific biological function, targets, or pathway associations for NBD-14270 are not provided in the Product Data. Without structural disclosure, no definitive biological roles can be assigned.

General guidance for small-molecule library members (non-clinical, research-only):

• May serve as a tool compound for exploratory screening across biochemical, cellular, or phenotypic assays.
• Potential to inform structure–activity relationships (SAR) once paired with activity data; confirm identity and purity before biological interpretation.
• Control for assay interference phenomena (PAINS, redox cyclers, aggregators, fluorescence/absorbance interference) using orthogonal readouts, detergent controls, and counter-screens. Apply cheminformatics filters when the structure is available.
• Ensure vehicle controls (DMSO-only) and evaluate compound stability in assay media (light, pH, and protein binding can impact apparent potency).

For any claims regarding mechanism or specificity, obtain and review the structure, then corroborate with primary data and orthogonal confirmation. No therapeutic or clinical use is implied or supported; the product is for research use only.

Buffer Applications

This catalog item is a small-molecule library member, not a buffering agent. No dedicated buffer system or pKa information is available.

Practical guidance for assay buffers when dosing small molecules (general):

• Prepare concentrated DMSO stocks, then dilute into assay buffers such as PBS, HBSS, HEPES, or Tris with careful control of final DMSO (typically 0.1–1% v/v).
• If compound is light sensitive, use amberware or foil-wrapped plates and minimize exposure during dosing.
• To mitigate nonspecific binding or aggregation, consider adding 0.01–0.05% Tween-20 or low levels of BSA if assay-compatible.
• Verify that buffer pH and ionic strength do not induce precipitation; inspect wells/solutions visually and by absorbance or light scattering when feasible.

Item-specific buffering properties, pKa, and solubility in defined buffers are not available for NBD-14270; refer to the CoA/Spec Sheet if provided with your lot.

Green Alternatives

Because the structure and specific use mode of NBD-14270 are not disclosed, solvent choice dominates the green profile for handling and analytics. Consider the following greener practices (general guidance):

• Dissolution: If DMSO is acceptable for your assay, it remains a relatively benign polar aprotic solvent compared with DMF or NMP. Where feasible, prefer EtOH or MeOH for quick analytical preparations when solubility allows.
• Chromatography: Favor ACN/H2O or MeOH/H2O with volatile buffers for LC over halogenated solvents. For flash chromatography, evaluate ethyl acetate/hexanes or IPA/EtOAc/Heptane blends over dichloromethane.
• Workup/clean-up: Minimize solvent volumes via microscale operations and adopt closed-vial evaporations to reduce emissions.

Comparison (general solvent considerations):

• DMSO vs DMF: DMSO offers similar solvency with a better EHS profile; DMF has reproductive toxicity concerns.
• ACN vs DCM: ACN is polar, LC-compatible, and less persistent; DCM is volatile and poses higher exposure risks.
• IPA/EtOAc/Heptane systems vs DCM-based systems: Reduced halogenated waste and often comparable separation power.

Tradeoffs: Solubility constraints may necessitate less-green solvents; document justification and implement engineering controls. For compound-specific greener options, consult the CoA (e.g., if salt form enables aqueous handling).

Pharmaceutical Uses

No pharmaceutical or excipient uses are provided for this item. NBD-14270 is supplied strictly for research use only (non-clinical), as indicated in the Product Data.

General context for small-molecule library compounds:

• These materials are commonly utilized in drug discovery research (target validation, screening, SAR) but are not qualified for human or veterinary administration.
• No pharmacopeial monograph, GMP status, or approved excipient role is implied. If formulation-like studies are undertaken (e.g., preformulation screening), ensure a suitable research-only quality system and do not extrapolate to clinical use.
• If you require a reagent for regulated applications, please contact us regarding availability of enhanced QC documentation or alternate grades.

Item-specific information such as dosage form suitability, impurities per pharmacopeia, residual solvent compliance, or extractables/leachables is not specified for this item; consult the CoA/Spec Sheet if such data are offered.

Physical Properties

Item-specific physicochemical specifications have not been provided in the Product Data for this library compound.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Melting/Boiling Point: Not specified for this item; refer to CoA/Spec Sheet.
• Density/Refractive Index: Not specified for this item; refer to CoA/Spec Sheet.
• Aqueous/Organic Solubility: Not specified for this item; refer to CoA/Spec Sheet.
• logP/logD, pKa: Not specified for this item; refer to CoA/Spec Sheet.

General laboratory guidance (literature/good practice):

• For unknown small molecules, begin dissolution screening with anhydrous DMSO (e.g., 10–50 mM stock), then evaluate compatibility with secondary solvents (MeOH, EtOH, acetonitrile, DMF) based on assay constraints.
• If the compound is light- or moisture-sensitive (storage guidance suggests light/moisture protection), minimize exposure during weighing and dissolution; use amber vials and a desiccated atmosphere.
• If a solid, determine approximate solubility by incremental solvent addition and gentle warming (≤40 °C) while avoiding prolonged heating. Filter particulates through 0.2 μm PTFE if needed before analytical use.
• For chromatographic method development, start with balanced eluents (e.g., ACN/H2O + 0.1% formic acid for LC-MS) and adjust based on retention and ionization response.

Always defer to the item-specific CoA/SDS for authoritative property data.

Quality and Grades

Grade/purity details are not provided in the Product Data for this library compound.

• Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.

Context for small-molecule library items (general information):

• Library entries are commonly supplied with LC/MS and/or 1H NMR identity confirmation and purity typically reported by LC-UV, LC-MS, or HPLC area %. Exact thresholds vary by supplier and lot; consult the CoA for this SKU.
• If applicable, stabilizers, counterions, or salt forms are listed on the CoA. The absence of a stabilizer statement here means details are unknown—verify prior to sensitive applications (e.g., photophysical assays).
• For analytical work (e.g., hit validation), we recommend independent confirmation: orthogonal purity assessment (LC-UV at multiple wavelengths, ELSD, HRMS), and if needed qNMR to quantify potency.
• If low-UV-absorbing solvents or additives are required (HPLC/UPLC), ensure your grade selection supports the analytical method (HPLC-grade solvents, 0.2 μm filtration) and verify that no excipients are present.

Contact us for the lot-specific CoA/Spec Sheet to confirm identity, purity method, assay %, residual solvents, and any stabilizers for NBD-14270 (SKU N1422238).

Reaction and Applications

This product is cataloged under small molecules/compound libraries and is typically utilized as a screening entity, not as a general synthetic reagent. No manufacturer reaction applications are provided for this item.

• Intended use (general):
  • Hit identification in HTS and fragment/lead discovery.
  • Benchmarking of assay performance, method development standards, or exploratory SAR.
• Assay implementation tips:
  • Prepare concentrated DMSO stocks (e.g., 10–50 mM); confirm solubility visually and analytically (UV/LC).
  • Use serial dilutions to generate dose-response curves; control final DMSO content to avoid assay artifacts.
  • Employ light protection during assay setup if compounds may be photolabile (amber plates/wrap).
• Analytical characterization:
  • Verify identity and purity upon receipt using LC-MS; optionally confirm by ^1H NMR.
  • Monitor compound stability over time by periodic LC-MS to detect degradation or hydrolysis, particularly if solutions are stored.
• Not typically applicable: Specific named reactions, catalysts, or synthetic methodologies cannot be recommended without structural information for NBD-14270.

For structure-driven applications (e.g., covalent warheads, photoprobes), request the detailed structure and CoA to ensure suitability and to design proper controls.

Reaction Conditions

No reaction conditions are specified for NBD-14270, and the compound is not positioned as a synthetic reagent in this listing.

General considerations if you plan downstream chemistry after obtaining the structure:

• Start with small-scale solvent screening (DMSO, DMF, MeCN, toluene, EtOH) and temperature windows based on functional group tolerance.
• Use analytical LC-MS to monitor conversions and to identify degradation channels (hydrolysis, photolysis, oxidation) suggested by the storage guidance (protect from light, desiccated).
• Adopt inert atmosphere techniques for moisture- or air-sensitive motifs; dryness can be critical for organometallic steps or acid chloride coupling chemistry.
• Typical times and yields are highly structure-dependent; consult primary literature once the functional groups are known.

For actionable, item-specific reaction guidance, obtain the full structural information and any supplier method notes associated with the lot’s CoA.

Safety and Handling

Hazard classifications and pictograms are not specified in the Product Data for this item; consult the SDS for authoritative guidance.

• GHS Classification / Signal Word / H-Statements / Pictograms: Not specified for this item; refer to SDS.
• General precautions (good laboratory practice):
  • Handle in a chemical fume hood; avoid inhalation, ingestion, and skin/eye contact.
  • Wear appropriate PPE: lab coat, safety glasses or face shield, and suitable chemically resistant gloves (e.g., nitrile); upgrade PPE based on SDS once available.
  • Storage guidance indicates protect from light and desiccation; minimize ambient exposure. Keep container tightly closed.
• Incompatibilities (general): Until specific functional groups are known, segregate from strong oxidizers, strong acids/bases, and reducing agents. Avoid reactive metals if the compound could be halogenated or acidic (verify with SDS/CoA).
• First aid (overview):
  • Skin: Wash with soap and water; remove contaminated clothing.
  • Eyes: Rinse with water for ≥15 minutes; seek medical attention.
  • Inhalation: Move to fresh air; obtain medical advice if symptoms persist.
  • Ingestion: Rinse mouth; do not induce vomiting unless directed by medical personnel.
• Spill/Disposal: Absorb small spills with inert material; dispose in accordance with institutional and local regulations. Prevent release to the environment.

Always consult the current SDS before extensive handling or scale-up.

Solvent Selection

No item-specific solubility profile is provided. The following is general guidance for handling unknown small molecules in discovery workflows.

• Primary stock solvent: Anhydrous DMSO is the default for HTS/biochemical assays due to broad solubilizing power and aqueous miscibility up to assay-compatible levels.
• Secondary solvents (if needed): DMF, acetonitrile, methanol, ethanol. Select based on assay tolerance, volatility, and downstream analytics (LC-MS compatibility).
• Aqueous work: Prepare concentrated DMSO stocks (e.g., 10–50 mM), then dilute into buffered aqueous media while keeping final DMSO ≤0.1–1% v/v as dictated by the biology.
• Photolability/Moisture sensitivity: Storage guidance indicates protection from light and desiccation—use amber vials, minimize headspace moisture, and avoid prolonged sonication or heating.
• Solvent screening tips:
  • Start small (100–500 μL) and titrate solvent until a clear solution is obtained.
  • Consider cosolvent blends (e.g., DMSO:ACN 1:1) to modulate viscosity and evaporation kinetics.
  • For poorly soluble materials, explore microliter additions of DMSO to aqueous media while monitoring precipitation.
• Analytical compatibility: For LC-MS, prefer ACN/H2O or MeOH/H2O with volatile modifiers (0.1% formic/acetic acid, 5–10 mM ammonium formate/acetate) depending on ionization mode.

For definitive solvent recommendations for NBD-14270, consult the lot-specific CoA/solubility note if available.

Storage and Reconstitution

Follow the item-specific storage guidance and best practices to maintain integrity.

• As supplied (solid or neat): Store at 2–8 °C, protected from light, desiccated. Keep container tightly closed. Shipped on wet ice.
• Reconstitution (general):
  • Dissolve in anhydrous DMSO to prepare a concentrated stock (e.g., 10–50 mM). Verify complete dissolution.
  • If aqueous use is required, dilute the DMSO stock into buffer while maintaining assay-compatible DMSO levels (typically 0.1–1% v/v).
• Aliquoting and light/moisture control: Prepare single-use amber aliquots to avoid repeated freeze–thaw and light exposure. Work quickly in a low-humidity environment or under dry gas if feasible.
• Storage of solutions (general good practice):
  • DMSO stocks: store at −20 °C to −80 °C, protected from light and moisture. Record preparation date and concentration.
  • Avoid multiple freeze–thaw cycles; thaw at room temperature, mix gently, and promptly return unused aliquots to cold, dark storage.
• Stability: Item-specific stability data are not provided; monitor by LC-MS/LC-UV at intervals to detect degradation.

For definitive shelf-life, solubility limits, and stability information for NBD-14270, consult the lot-specific CoA/Spec Sheet and SDS.

Structure and Identity

This product is supplied as part of a small-molecule/compound library entry. Item-specific structural identifiers have not been disclosed in the Product Data.

• Product Name: NBD-14270 (SKU: N1422238)
• CAS: 2411819-82-2
• Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.

Structural features (functional groups, ring systems, stereochemistry) are not provided for this catalog entry. If you require definitive identity elements (e.g., exact 2D/3D structure, tautomers, and stereochemical descriptors), please request the latest CoA/SDS and specification package. For cheminformatics workflows, we recommend obtaining the native structure file (SDF/MOL) when available to avoid transcription errors from line notations.

Synthetic Utility

This product is listed as a small-molecule library member intended primarily for screening and analytical research. Without structural disclosure, no specific synthetic transformations or named-reaction roles can be recommended for NBD-14270.

General guidance (applicable when structure is available):

• If used as a reference standard or analytical spike, verify purity by orthogonal means (LC-UV, LC-MS, qNMR) and store under light/moisture protection.
• If the compound contains common functional handles (e.g., halides, boronates, amines, acids), suitable transformations may include cross-couplings, amide couplings, nucleophilic substitutions, or late-stage functionalizations. Do not assume compatibility—confirm after obtaining the structural information.
• For method development, characterize polarity (Rt in reverse-phase LC), ionization behavior (ESI+/−), and stability (pH/light), then design synthetic or derivatization steps accordingly.

Item-specific synthetic reactivity and protecting-group strategies are not specified for this SKU; please refer to the CoA or contact technical support to discuss feasibility once structure details are available.

Target Specificity

Target, pathway, or enzyme/receptor specificity is not provided for NBD-14270.

• Target/Pathway: Not specified for this item; refer to CoA/Spec Sheet.
• Assay Validations: Not specified for this item; refer to CoA/Spec Sheet.

If using this compound in screening:

• Incorporate orthogonal assays and appropriate counter-screens to identify off-target effects or assay interference.
• Apply cheminformatics filters (once structure is available) to flag potential interference chemotypes and to prioritize confirmatory testing.

No inference of biological target or selectivity should be made without direct data.